— no lab draws, no clinician interpretation required.

Initial clinical applications target postoperative bleeding (up to 23M at-risk U.S. surgical patients annually) and postpartum hemorrhage, the #1 cause of maternal death worldwide. The device works under motion, across all skin tones, and in both hospital and remote settings.

Backed by two NIH CAPCaT awards, with $500K+ raised through federal grants, convertible notes, and angel investors. U.S. patent pending. R&D partnerships with UT Austin, WPI, UCI, and UMass Chan Medical School. FDA 510(k) submission targeted early 2027.